923032-59-1

Basic information

• Product Name: 1-Allylcyclopropane-1-sulfonyl chloride
• Synonyms: 1-Allylcyclopropanesulfonyl chloride;1-Allylcyclopropane-1-sulfonyl chloride;1-(2-Propen-1-yl)cyclopropanesulfonyl Chloride;1-(prop-2-en-1-yl)cyclopropane-1-sulfonyl chloride
• CAS NO: 923032-59-1
• Molecular Formula: C6H9ClO2S
• Molecular Weight: 180.65
• Product Categories: sulfonyl compound;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfonyl Chlorides
• Mol File: 923032-59-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 229.2 °C at 760 mmHg
• Flash Point: 92.4 °C
• Appearance: yellow oil
• Density: 1.32 g/cm³
• Refractive Index: 1.515
• Storage Temp.: Hygroscopic, Refrigerator, Under Inert Atmosphere
• Solubility: Chlroform
• CAS DataBase Reference: 1-Allylcyclopropane-1-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Allylcyclopropane-1-sulfonyl chloride(923032-59-1)
• EPA Substance Registry System: 1-Allylcyclopropane-1-sulfonyl chloride(923032-59-1)

Safety Data

• Hazardous Substances Data: 923032-59-1(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Oil

Uses

As a MEK inhibitors, 1-Allylcyclopropane-1-sulfonyl chloride can be useful in the treatment of cancer and other hyperproliferative diseases.

InChI:InChI=1/C6H9ClO2S/c1-2-3-6(4-5-6)10(7,8)9/h2H,1,3-5H2

Upstream product

• 923032-56-8 butyl 1-allylcyclopropane-1-sulfonate 
• 923032-57-9 potassium 1-allylcyclopropane-1-sulfonate 

Relevant articles and documents

BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS

This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administred to a Hepatocellu

NOVEL 6-ARYLAMINO PYRIDONE SULFONAMIDES AND 6-ARYLAMINO PYRAZINONE SULFONAMIDES AS MEK INHIBITORS

The invention provides novel substituted 6-arylamino pyridone sulfonamides and 6 arylamino pyrazinone sulfonamides represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans